Catalent Launches New Business Unit - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Launches New Business Unit
The new unit aligns existing modified-release and medication-delivery businesses of the company.


The CDMO Catalent Pharma Solutions has created a new business unit, Advanced Delivery Technologies, which aligns the company’s existing modified-release and medication-delivery businesses, including biologics technologies and capabilities.

The new business unit will operate eight development and manufacturing facilities globally. These facilities include: those for fast-dissolve technologies at Swindon, United Kingdom; controlled-release technologies in Winchester, Kentucky, which is currently undergoing a major expansion, the recently expanded Schorndorf, Germany site; the advanced drug-development center in Somerset, New Jersey, the new biologics center of excellence in Madison, Wisconsin; advanced aseptic production in Woodstock, Illinois; and prefilled syringe facilities in Brussels, Belgium and Limoges, France.

The new business unit of Advanced Delivery Technologies complements existing business units for softgel technologies and development and Development and clinical services.

Barry Littlejohns has been named president of the new business unit. He has more than 25 years of experience in the drug-delivery industry spanning oral dose forms, parenteral delivery and biologics. “Our industry is facing tough challenges with increasingly difficult molecules, requiring more sophisticated development expertise, delivery technologies and supply capabilities to optimize bioavailability, therapeutic profiles and clinical outcomes,” he said in a company press release.“By bringing together talent and expertise from two proven teams, with our extensive intellectual property, technology and manufacturing platforms, we expect to partner with innovators around the world to deliver the most innovative, advanced and effective solutions to help bring more products to market faster and improve the efficacy of their treatments."

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here